Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03899857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab for Newly Diagnosed Glioblastoma

Study acronym: PERGOLA
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 8, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Feb 2024 to Apr 30, 2026 Completion date: Dec 2024 to Dec 2026v6 Show 1 more changeShow less
    • Completion date: Dec 2024 to Dec 2026
  2. Primary completion date: Dec 2022 to Feb 2024 Completion date: Dec 2023 to Dec 2024v5 Show 1 more changeShow less
    • Completion date: Dec 2023 to Dec 2024
  3. Trial status: Recruiting to Active, Not Recruiting Site details revised at 3 of 3 sitesv4 Show 1 more changeShow less
    • Site details revised at 3 of 3 sites
  4. Study sites: 1 to 3v3
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2019 to Oct 21, 2020 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date changed from estimate of May 2019 to Oct 21, 2020
    • Study sites: 0 to 1
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.
Trial Details
NCT Number NCT03899857
Lead Sponsor University of Zurich
Collaborators: Merck Sharp & Dohme LLC
Conditions Newly Diagnosed Glioblastoma
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov